NCT01304836已完成4 期
Investigating New Onset Diabetes Mellitus in Kidney Transplant Recipients Receiving an Advagraf-Based Immunosuppressive Regimen With or Without Corticosteroids - A Multicenter, Two Arm, Randomized, Open Label Clinical Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 1,166
- 主要终点
- Diagnosis of new onset Diabetes Mellitus as per ADA criteria at any point up to 24 weeks after kidney transplantation
研究概览
简要总结
The purpose of this study is to focus on potential differences in the occurrence of new-onset Diabetes Mellitus (a glucose metabolism disorder) when two different regimens of immunosuppressive treatment are compared.
详细描述
The primary objective of this study is to compare an Immunosuppressive regimen with 10 days of corticosteroids with a regimen with only an optional intra-op bolus of corticosteroids with regard to incidence of new onset Diabetes Mellitus as per the American Diabetic Association (ADA) criteria at any point up to 24 weeks after kidney transplantation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •End stage kidney disease and a suitable candidate for primary
- •kidney transplantation or re-transplantation (unless the graft was
- •lost from rejection within one year)
- •Receiving a kidney transplant from a deceased or living (non
- •Human Leukocyte Antigen identical) donor with compatible AB0 blood type
- •Female subjects of childbearing potential must have a
- •negative serum or urine pregnancy test at enrollment and must
- •agree to maintain highly effective birth control during the study.
- •A highly effective method of birth control is defined as those
- •which result in a low failure rate (CPMP/ICH/286/95 modified)
- •of less than 1% per year when used consistently and correctly
- •such as implants, injectables, combined oral contraceptives,
- •some IUDs, sexual abstinence or vasectomized partner
排除标准
- •Receiving or having previously received an organ transplant
- •other than a kidney
- •Cold ischemia time of the donor kidney > 30 hours
- •Panel Reactive Antibody >20% (Highest level in 6 months prior to transplant)
- •Previous renal transplant lost within one year for immunological reasons
- •Receiving a graft from a non-heart-beating donor other than of Maastricht category 3 (withdrawal of support awaiting cardiac arrest)
- •Significant liver disease, defined as having continuously
- •elevated SGPT/ALT and/or SGOT/AST and/or total bilirubin
- •levels ≥ 2 times the upper value of the normal range of the
- •investigational site or is receiving a graft from a hepatitis C or B
- •positive donor
- •Diagnosis of Diabetes Mellitus prior to transplantation (treated with prescribed medications or diet controlled) or where there is evidence of a previous positive Oral Glucose Tolerance Test (OGTT) in the patients medical history or previous diagnosis of gestational diabetes or pre-baseline HbA1C ≥6.5%
- •Requiring initial sequential or parallel therapy with immunosuppressive antibody preparation(s).
- •Requiring ongoing dosing with a systemic immunosuppressive drug prior to transplantation (e.g. for Lupus Disease, FSGN etc) other than minimal levels of immunosuppressant following failure of a previous transplantation without nephrectomy
- •Where Physician considers long term steroid treatment is necessary for the prevention of recurrent auto immune mediated renal disease or if the subject requires ongoing dosing with corticosteroids during the study for any other condition
- •Significant, uncontrolled concomitant infections and/or severe diarrhea, vomiting, active upper gastro-intestinal tract malabsorption or active peptic ulcer
- •Pregnant woman or breast-feeding mother
- •Subject or donor known to be HIV positive
- •Known allergy or intolerance to tacrolimus, macrolide antibiotics, corticosteroids, basiliximab, mycophenolate mofetil or any of the product excipients
- •Evidence of malignant disease within the last 5 years other than Basal Cell Carcinoma or Squamous Cell Carcinoma
- •Currently participating in another clinical trial and/or has taken an investigational drug within 28 days prior to randomization
- •Any form of substance abuse, psychiatric disorder or condition which, in the opinion of the investigator, may complicate communication with the investigator
- •Unlikely to comply with the visits scheduled in the protocol
研究组 & 干预措施
10 Days of Steroids
Active Comparator
Advagraf + Basiliximab + MMF + Steroids (10 days)
干预措施: Advagraf (Drug)
10 Days of Steroids
Active Comparator
Advagraf + Basiliximab + MMF + Steroids (10 days)
干预措施: Mycophenolate Mofetil (Drug)
10 Days of Steroids
Active Comparator
Advagraf + Basiliximab + MMF + Steroids (10 days)
干预措施: Simulect (Drug)
10 Days of Steroids
Active Comparator
Advagraf + Basiliximab + MMF + Steroids (10 days)
干预措施: Corticosteroids (Drug)
Optional Steroid bolus only
Experimental
Advagraf + Basiliximab + MMF + Steroids (bolus only)
干预措施: Advagraf (Drug)
Optional Steroid bolus only
Experimental
Advagraf + Basiliximab + MMF + Steroids (bolus only)
干预措施: Mycophenolate Mofetil (Drug)
Optional Steroid bolus only
Experimental
Advagraf + Basiliximab + MMF + Steroids (bolus only)
干预措施: Simulect (Drug)
Optional Steroid bolus only
Experimental
Advagraf + Basiliximab + MMF + Steroids (bolus only)
干预措施: Corticosteroids (Drug)
结局指标
主要结局
Diagnosis of new onset Diabetes Mellitus as per ADA criteria at any point up to 24 weeks after kidney transplantation
时间窗: up to 6 months
次要结局
- Acute Rejections(up to 6 months)
- Graft survival(up to 6 months)
- Repeat Positive Oral Glucose Tolerance Test(6 months)
- Change from Baseline in HbA1C levels(Baseline, week 12 and week 24)
- Efficacy failure using a composite endpoint consisting of graft loss, biopsy confirmed acute rejection or graft dysfunction(up to 6 months)
- Renal function(at 6 months)
- Positive Oral Glucose Tolerance Test(8 weeks)
- Biopsy confirmed acute rejections(up to 6 months)
- Subject survival(up to 6 months)
研究者
相似试验
已完成
4 期
Investigating new onset diabetes mellitus in kidney transplant recipients receiving an Advagraf-based immunosupressive regimen with or without corticosteroids - A multicenter, two arm, randomized, open label clinical study.Kidney transplantationtransfer of a healthy kidney in another body with non-functioning kidneys.10029149NL-OMON38176Astellas Pharma B.V.15
已完成
不适用
Examination of the Pancreas in New-onset DiabetesDiabetes MellitusNCT02001337Mayo Clinic79
进行中（未招募）
不适用
Studying the onset of Diabetes Mellitus in patients with a kidney tranplant getting anti-rejection therapy with Advagraf when used with or without steroids.EUCTR2010-019638-28-EEAstellas Pharma Europe Ltd.1,166
进行中（未招募）
1 期
INVESTIGATING NEW ONSET DIABETES MELLITUS IN KIDNEY TRANSPLANT RECIPIENTS RECEIVING AN ADVAGRAF-BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT CORTICOSTEROIDS – A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY - ADVANCEEUCTR2010-019638-28-SKAstellas Pharma Europe Ltd.1,166
进行中（未招募）
不适用
Studying the onset of Diabetes Mellitus in patients with a kidney tranplant getting anti-rejection therapy with Advagraf when used with or without steroids.EUCTR2010-019638-28-LTAstellas Pharma Europe Ltd.1,166